{"entity":{"id":"te-1182","kind":"drug","name":"TE-1182","aka":[],"tldr":"TE-1182 is an experimental antibody-drug conjugate from T-E Meds that carries two different cell-killing drugs to cancer cells with HER2 on their surface. It has been tested only in the laboratory, and the FDA has given it orphan drug status for gastric cancer.","summary":"TE-1182 is a HER2-directed antibody-drug conjugate developed by T-E Meds on the CHO-TEM platform established with CHO Pharma, which produces the trastuzumab antibody. Each antibody carries four T-E Meds drug bundles with one MMAF and one exatecan each (eight payload molecules). The company reports that in cell lines with high, moderate (trastuzumab deruxtecan-resistant) and low HER2 expression it was more cytotoxic than trastuzumab deruxtecan, and that it inhibited tumour growth in a JIMT-1 xenograft model; these are preclinical results. On 6 October 2026 the FDA granted orphan drug designation for the treatment of gastric cancer to a trastuzumab-MMAF/exatecan dual-payload antibody-drug conjugate sponsored by T-E Meds.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"T-E Meds: TE-1182","url":"https://www.temeds.com/te-1182/"},{"label":"FDA orphan designation record","url":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145626"}],"tags":["pipeline","orphan-designation"],"related":[],"cancers":["gastric"],"sections":[],"technologies":["dual-payload-adc"],"targets":["her2"],"drugs":[],"companies":["t-e-meds"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"TE-1182","modality":"Dual-payload antibody-drug conjugate","payload":"MMAF and exatecan","mechanism":"Trastuzumab, an antibody against HER2, is site-specifically conjugated to four drug bundles, each carrying one MMAF (a microtubule inhibitor) and one exatecan (a topoisomerase I inhibitor), giving a drug-to-antibody ratio of 8 with two payloads of different mechanism, as the developer describes it.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[{"date":"2026-10-06","type":"designation","region":"US","note":"FDA orphan drug designation for gastric cancer, granted to T-E Meds for a trastuzumab-MMAF/exatecan dual-payload antibody-drug conjugate","source":"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1145626","indication":"treatment of gastric cancer"}]},"route":"/drugs/te-1182/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"technology":[{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"t-e-meds","kind":"company","name":"T-E Meds","route":"/companies/t-e-meds/"}]}}